NASA astronauts Sunita Williams, and Barry 'Butch' Wilmore returned to Earth after spending over 9 months in microgravity.

Differences in the distribution of certain proteins and markers in the brain may explain why some people first experience ...

Spending lower proportions of time in two deep sleep stages — including REM sleep — may be linked to volume changes in critical brain regions that can be vulnerable to Alzheimer’s disease, a new study ...

Associations seen between less short wave sleep and rapid eye movement sleep with smaller inferior parietal region volumes.

Proud C, et al. Intrathecal onasemnogene abeparvovec for patients with spinal muscular atrophy: Phase 3 randomized, sham-controlled, double-blind STEER study. Presented at: Muscular Dystrophy ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.

A new study shows that weight training not only boosts physical strength but also protects the brains of older adults with mild cognitive impairment.

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease. (Journal of Clinical Sleep Medicine) Researchers assessed evidence ...